A5081339832- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Economic and Financial Impacts of Cancer
- Colorectal Cancer Treatments and Studies
- Ethics in Clinical Research
- Neuroendocrine Tumor Research Advances
- Health Systems, Economic Evaluations, Quality of Life
- Health and Medical Research Impacts
- COVID-19 and healthcare impacts
- Prostate Cancer Diagnosis and Treatment
- Biomedical Ethics and Regulation
- Advances in Oncology and Radiotherapy
- Prostate Cancer Treatment and Research
- Biomedical and Engineering Education
- Statistical Methods in Clinical Trials
- Hormonal and reproductive studies
- Healthcare cost, quality, practices
Michigan Cancer Research Consortium
2017-2025
Clovis Oncology (United Kingdom)
2023
Gilead Sciences (United States)
2023
Bristol-Myers Squibb (Germany)
2023
Boehringer Ingelheim (India)
2023
Incyte (United States)
2023
Janssen (Switzerland)
2023
Pharmacyclics (United States)
2023
Ipsen (France)
2023
Mirati Therapeutics (United States)
2023
Androgens are involved in the development of prostate cancer. Finasteride, an inhibitor 5α-reductase, inhibits conversion testosterone to dihydrotestosterone, primary androgen prostate, and may reduce risk
This report presents the American Society of Clinical Oncology's (ASCO's) evaluation adaptations in care delivery, research operations, and regulatory oversight made response to coronavirus pandemic recommendations for moving forward as recedes. ASCO organized its clinical around five goals ensure lessons learned from COVID-19 experience are used craft a more equitable, accessible, efficient system that protects patient safety, ensures scientific integrity, maintains data quality. The...
A survey of clinical research professionals @SWOG indicate that 80% trial offices are understaffed. Addressing this is critical so progress for people with cancer continues. Read more about lessons learned in the #COVID19 pandemic and how it informs a path forward.
Clinical research program managers are regularly faced with the quandary of determining how much a workload staff members can manage while they balance clinical practice and still achieve trial accrual goals, maintain data quality protocol compliance, stay within budget. A tool was developed to measure trial-associated workload, apply objective metrics toward documentation work, provide clearer insight better meet challenges aid in balancing workloads. project conducted assess feasibility...
11049 Background: Severe shortages in clinical trial staffing across the United States and internationally has been anecdotally noted, but data are lacking. To better assess scope impact of shortages, SWOG conducted a Cooperative Group-wide survey Oncology Research Professionals (ORP). Methods: The was developed by leadership granted an IRB exemption Lifespan (Providence, RI). disseminated email January 2022 to Head Clinical Associates (CRAs, n = 100) using inclusive distribution list that...
The conduct of clinical cancer research has faced considerable challenges in recent years, and the situation only been exacerbated by global pandemic. growing complexity trials rising administrative burdens had causing greater expense difficulty recruiting retaining an appropriately trained workforce even before well-publicized increase turnover caused Longstanding issues such as restrictive inclusion criteria complicated trial designs have negatively affected already low accrual rates,...
Abstract Prior studies suggest that tumor cell lines harboring RAS mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response rate combination these drugs. Forty chemo-naïve nonresectable histologically confirmed cancer were accrued. Patients received 1,000 mg/m2 (days 1 8) etoposide 80 8, 9, 10; 21-day cycle). The primary end point was radiological rate....
Abstract Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy finasteride for prevention prostate cancer with primary outcome histologically determined prevalence at end 7 years. Methods: A systematic modeling process using logistic regression identified factors available year 6 that are associated end-of-study (EOS) biopsy adherence 7, stratified by whether participants were ever prompted 6. Final models...
Purpose: Clinical trial billing compliance is a challenge that faced by overburdened clinical trials sites. The requirements place institutions and research sites at increased potential for financial risk. To reduce their risk, develop coverage analysis (CA) before opening each trial. For multisite trials, this translates into system-wide redundancies, inconsistencies, delays, costs to patients. These factors exacerbate low accrual rates cancer trials. ASCO the National Cancer Institute...
6542 Background: Since the implementation of ACA, many insurers have followed Medicare’s lead in covering routine care costs associated with clinical trials (CTs). However, questions remain on how to distinguish from non-billable research costs, and this has important financial implications for both sites patients. As a result, individually conduct coverage analyses (CAs) prior opening CTs determine billable costs. This is significant duplication effort NCI network that are open at hundreds...
Supplementary Form 1 from Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Supplementary Form 1 from Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
<div>Abstract<p>Prior studies suggest that tumor cell lines harboring <i>RAS</i> mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response rate combination these drugs. Forty chemo-naïve nonresectable histologically confirmed cancer were accrued. Patients received 1,000 mg/m<sup>2</sup> (days 1 8) etoposide 80 8, 9, 10;...
<div>Abstract<p>Prior studies suggest that tumor cell lines harboring <i>RAS</i> mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response rate combination these drugs. Forty chemo-naïve nonresectable histologically confirmed cancer were accrued. Patients received 1,000 mg/m<sup>2</sup> (days 1 8) etoposide 80 8, 9, 10;...